Author: "Buti S" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Buti S"' showing total 580 results

Start Over Author "Buti S"

580 results on '"Buti S"'

101. A1033 - Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study.

Author: Ciccarese, C., Buti, S., Roberto, M., Calabrò, F., Masini, C., Massari, F., Cannella, M., Mazzaschi, G., Astore, S., Di Girolamo, S., Panebianco, M., Mollica, V., Granitto, A., Fiorentino, V., Pierconti, F., Martini, M., Porta, C., Tortora, G., and Iacovelli, R.
Subjects: *RENAL cell carcinoma, *PROGRAMMED death-ligand 1, *TREATMENT effectiveness, *BIOMARKERS, *PROGNOSIS
Published: 2023
Full Text: View/download PDF

102. LOH as “the missing instability” potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer

Author: Bersanelli, M., primary, Gnetti, L., additional, Azzoni, C., additional, Bottarelli, L., additional, Gasparro, D., additional, Leonardi, F., additional, Silini, E.M., additional, and Buti, S., additional
Published: 2016
Full Text: View/download PDF

103. First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

Author: Bersanelli, M., primary, Maines, F., additional, Facchini, G., additional, Gelsomino, F., additional, Zustovich, F., additional, Santoni, M., additional, Verri, E., additional, De Giorgi, U., additional, Masini, C., additional, Morelli, F., additional, Vitale, M.G., additional, Sava, T., additional, Prati, G., additional, Librici, C., additional, Fraccon, A.P., additional, Fornarini, G., additional, Maruzzo, M., additional, Leonardi, F., additional, Caffo, O., additional, and Buti, S., additional
Published: 2016
Full Text: View/download PDF

104. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors

Author: Santoni, M, Conti, A, Partelli, S, Porta, C, Sternberg, Cn, Procopio, G, Bracarda, S, Basso, U, De Giorgi, U, Derosa, L, Rizzo, M, Ortega, C, Massari, F, Iacovelli, Roberto, Milella, M, Di Lorenzo, G, Buti, S, Cerbone, L, Burattini, L, Montironi, R, Santini, D, Falconi, M, Cascinu, S, Iacovelli, R, Albiges, L, Loriot, Y, Massard, C, Fizazi, K, Escudier, B, Pietrantonio, F, Di Bartolomeo, M, de Braud, F, Verzoni, E, Braud, Fd, Testa, I, Grassi, P, Galli, G, De Braud, F, Saravia, D, Salvioni, R, Farcomeni, Alessio, Maggi, C, Palazzo, A, Ricchini, F, Porcu, L, Torri, V, Masini, C, Atzori, F, Pagano, M, De Vivo, R, Mosca, A, Rossi, M, Paglino, C, Muzzonigro, G, Fanetti, G, Deraco, M, Perrone, F, Baratti, D, Kusamura, S, Tamborini, E, Castano, A, Consonni, Pv, Bossi, I, Gavazzi, C, Milione, M, Pelosi, G, Orlando, V, Cortesi, E, Biondani, P, Garanzini, E, Facciorusso, Mg, Testi, A, Miceli, R, Leone, G, de Braud, F., Santoni, Matteo, Conti, Alessandro, Porta, Camillo, Sternberg Cora, N., Procopio, Giuseppe, Bracarda, Sergio, Basso, Umberto, De Giorgi, Ugo, Derosa, Lisa, Rizzo, Mimma, Ortega, Cinzia, Massari, Francesco, Iacovelli, Roberto, Milella, Michele, Di Lorenzo, Giuseppe, Buti, Sebastiano, Cerbone, Linda, Burattini, Luciano, Montironi, Rodolfo, Santini, Daniele, Falconi, Massimo, Cascinu, Stefano, and Partelli, Stefano
Subjects: Oncology, Male, medicine.medical_treatment, urologic and male genital diseases, Gastroenterology, Nephrectomy, Metastasis, Surgical oncology, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine, Aged, 80 and over, Middle Aged, Protein-Tyrosine Kinases, Prognosis, Combined Modality Therapy, female genital diseases and pregnancy complications, Kidney Neoplasms, Survival Rate, Local, Lymphatic Metastasis, Female, Adult, medicine.medical_specialty, Internal medicine, Carcinoma, Humans, Neoplasm Invasiveness, Survival rate, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Retrospective Studies, business.industry, Renal Cell, Cancer, medicine.disease, not applicable, Pancreatic Neoplasms, Neoplasm Recurrence, Concomitant, Surgery, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract: The aim of this study was to compare survival of resected and unresected patients in a large cohort of patients with metastases to the pancreas from renal cell carcinoma (PM-RCC). Data from 16 Italian centers involved in the treatment of metastatic RCC were retrospectively collected. The Kaplan–Meier and log-rank test methods were used to evaluate overall survival (OS). Clinical variables considered were sex, age, concomitant metastasis to other sites, surgical resection of PM-RCC, and time to PM-RCC occurrence. Overall, 103 consecutive patients with radically resected primary tumors were enrolled in the analysis. PM-RCCs were synchronous in only three patients (3 %). In 56 patients (54 %), the pancreas was the only metastatic site, whereas in the other 47 patients, lung (57 %), lymph nodes (28 %), and liver (21 %) were the most common concomitant metastatic sites. Median time for PM-RCC occurrence was 9.6 years (range 0–24 years) after nephrectomy. Surgical resection of PM-RCC was performed in 44 patients (median OS 103 months), while 59 patients were treated with tyrosine kinase inhibitors (TKIs; median OS 86 months) (p = 0.201). At multivariate analysis, Memorial Sloan Kettering Cancer Center risk group was the only independent prognostic factor. None of the other clinical variables, such as age, sex, pancreatic surgery, or the presence of concomitant metastases, were significantly associated with outcome in PM-RCC patients. The presence of PM-RCC is associated with a long survival, and surgical resection does not improve survival in comparison with TKI therapy. However, surgical resection leads to a percentage of disease-free PM-RCC patients.
Published: 2014

105. 891P - Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study

Author: Vitale, M.G., Pipitone, S., Scagliarini, S., Zucali, P.A., Galli, L., Rossetti, S., Caserta, C., Iacovelli, R., Masini, C., Ficorella, C., Di Girolamo, S., Buti, S., Benedetti, B., Santoni, M., Porta, C., Bracarda, S., Baldessari, C., Giaquinta, S., Cascinu, S., and Sabbatini, R.
Published: 2018
Full Text: View/download PDF

106. 885P - Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)

Author: Verzoni, E., Cartenì, G., Cortesi, E., Roila, F., Vitale, M.G., Buti, S., Pignata, S., Cognetti, F., Giustini, L., Damiani, A., Turci, D., Sternberg, C.N., Porta, C., Carrozza, F., Tortora, G., Tassinari, D., Passalacqua, R., Pazzola, A., Surico, G., and Procopio, G.
Published: 2018
Full Text: View/download PDF

107. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: A retrospective Italian survey

Author: Masini, C., Sabbatini, R., Porta, C., Procopio, G., Di Lorenzo, G., Onofri, A., Buti, S., Iacovelli, R., Invernizzi, R., Moscetti, L., Aste, M. G., Pagano, M., Grosso, F., Lucia Manenti, A., Ortega, C., Cosmai, L., Del Giovane, C., and Conte, P. F.
Subjects: Male, Niacinamide, renal cell carcinoma, Indoles, Pyridines, Antineoplastic Agents, Renal Dialysis, haemodialysis, tyrosine kinase inhibitors, Sunitinib, Humans, Pyrroles, Neoplasm Metastasis, Protein Kinase Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Contraindications, Phenylurea Compounds, Benzenesulfonates, Middle Aged, Sorafenib, Kidney Neoplasms, Kidney Failure, Chronic, Female
Abstract: What's known on the subject? and What does the study add? Sunitinib and sorafenib are orally administered multikinase inhibitors approved for the treatment of advanced RCC. The limited pharmacokinetics data on sunitinib and sorafenib suggest that haemodialysis does not significantly alter plasma concentrations. In this retrospective study we define the safety and efficacy of tyrosine kinase inhibitors in patients with metastatic RCC (mRCC) and end-stage renal disease requiring haemodialysis. Even though the retrospective nature of this survey and the relatively small sample size represent major limitations, these data indicate that treatment with sunitinib and sorafenib in this cohort of patients is feasible with no unexpected toxicity and good efficacy, results similar to those in the general population of patients with mRCC.To investigate the safety and efficacy of tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring haemodialysis (HD).Between July 2006 and December 2010, 24 patients undergoing HD were treated with sunitinib and/or sorafenib for mRCC in 14 Italian institutions. We retrospectively reviewed the medical records of these patients to evaluate the administered doses of TKIs, treatment-related toxicities and the clinical response to therapy.Sunitinib was administered at 50 mg daily for 4-6 weeks in six patients, 37.5 mg daily for 4-6 weeks in seven patients (one patient subsequently increased the dose to 50 mg daily), 25 mg daily for 4-6 weeks in two patients and 12.5 mg daily for 4-6 weeks in one patient. Among the eight patients treated with sorafenib, four patients received 800 mg daily (400 mg every 12 h), three patients 400 mg daily and one patient 200 mg daily with a continuous schedule. The estimated median progression-free and overall survival periods of this cohort of patients were 10.3 months and 22.6 months, respectively. With regard to tolerability and safety, no unexpected adverse events were registered and no grade 4 haematological or non-haematological toxicities were reported.Sunitinib and sorafenib treatment is not contraindicated in patients with mRCC undergoing HD. The outcome of this patient population is similar to that observed in patients with normal renal function treated with TKIs. These results merit further confirmation by a larger prospective trial.
Published: 2012

108. Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

Author: Santini, D., primary, Santoni, M., additional, Conti, A., additional, Procopio, G., additional, Verzoni, E., additional, Galli, L., additional, Di Lorenzo, G., additional, De Giorgi, U., additional, De Lisi, D., additional, Nicodemo, M., additional, Maruzzo, M., additional, Massari, F., additional, Buti, S., additional, Biasco, E., additional, Ricotta, R., additional, Porta, C., additional, Vincenzi, B., additional, Marchetti, P., additional, Cascinu, S., additional, and Tonini, G., additional
Published: 2015
Full Text: View/download PDF

109. 2603 Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

Author: Santini, D., primary, Santoni, M., additional, Conti, A., additional, Procopio, G., additional, Verzoni, E., additional, Galli, L., additional, Di Lorenzo, G., additional, De Giorgi, U., additional, De Lisi, D., additional, Nicodemo, M., additional, Maruzzo, M., additional, Massari, F., additional, Buti, S., additional, Biasco, E., additional, Ricotta, R., additional, Porta, C., additional, Vincenzi, B., additional, Marchetti, P., additional, Cascinu, S., additional, and Tonini, G., additional
Published: 2015
Full Text: View/download PDF

110. IL CARCINOMA DEL COLON RETTO NELL'ANZIANO: CHIRURGIA OPEN E LAPAROSCOPICA

Author: Buti, S, Ferretti, P, Grilli, P, Romano, N, Calvaruso, V, and Goletti, Orlando
Published: 2010

111. 58P - Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study

Author: Bersanelli, M., Castrignanò, P., Gambale, E., Cortellini, A., Tiseo, M., Natoli, C., Ficorella, C., Panni, S., Rossetti, S., Papa, A., Mazzoni, F., Facchini, G., De Giorgi, U., Procopio, G., Atzori, F., Sava, T., De Luca, E., Maestri, A., Massari, F., and Buti, S.
Published: 2017
Full Text: View/download PDF

112. E20 - Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab

Author: Tiseo, M., Facchinetti, F., Buti, S., Gelsomino, F., Veneziani, M., Squadrilli, A., Bordi, P., Bersanelli, M., Cosenza, A., Ferri, L., Rapacchi, E., Mazzaschi, G., Leonardi, F., Quaini, F., Ardizzoni, A., and Missale, G.
Published: 2017
Full Text: View/download PDF

113. B1* - CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Author: Masini, C., Vitale, M.G., Maruzzo, M., Procopio, G., De Giorgi, U., Buti, S., Rossetti, S., Iacovelli, R., Guida, A., Atzori, F., Mucciarini, C., Cosmai, L., Vignani, F., Prati, G., Scagliarini, S., Berselli, A., and Pinto, C.
Published: 2017
Full Text: View/download PDF

114. 1643P - Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab

Author: Tiseo, M., Facchinetti, F., Gelsomino, F., Buti, S., Veneziani, M., Squadrilli, A., Bordi, P., Bersanelli, M., Cosenza, A., Ferri, L., Rapacchi, E., Mazzaschi, G., Leonardi, F., Quaini, F., Ardizzoni, A., and Missale, G.
Published: 2017
Full Text: View/download PDF

115. 904P - Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)

Author: De Giorgi, U., Procopio, G., Guida, A., Bearz, A., Buti, S., Basso, U., Mitterer, M., Ortega, C., Bidoli, P., Ferrau, F., Crinò, L., Frassoldati, A., Marchetti, P., Mini, E., Scoppola, A., Verusio, C., Fornarini, G., Cartenì, G., Caserta, C., and Sternberg, C.N.
Published: 2017
Full Text: View/download PDF

116. 905P - CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Author: Masini, C., Vitale, M.G., Maruzzo, M., Procopio, G., De Giorgi, U., Buti, S., Rossetti, S., Iacovelli, R., Guida, A., Atzori, F., Mucciarini, C., Scagliarini, S., Vignani, F., Prati, G., Cosmai, L., Berselli, A., and Pinto, C.
Published: 2017
Full Text: View/download PDF

117. 901P - Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Author: Procopio, G., Prisciandaro, M., Iacovelli, R., Mancini, M., Fornarini, G., Facchini, G., Cartenì, G., Napolitano, M., Sternberg, C.N., Caserta, C., Bregni, M., Massari, F., Buti, S., Biasco, E., De Giorgi, U., Zustovich, F., Ratta, R., Ortega, C., Tortora, G., and Verzoni, E.
Published: 2017
Full Text: View/download PDF

118. 887P - Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)

Author: Bracarda, S., Galli, L., Maruzzo, M., Lo Re, G., Buti, S., Favaretto, A., Costanzo, F.D., Sacco, C., Merlano, M., Mucciarini, C., Zafarana, E., Romito, S., Maestri, A., Giannitto Giorgio, C., Ionta, M.T., Turci, D., De Giorgi, U., Procopio, G., Cortesi, E., and Porta, C.
Published: 2017
Full Text: View/download PDF

119. 30PD_PR - Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab

Author: Tiseo, M., Veneziani, M., Gelsomino, F., Facchinetti, F., Bordi, P., Rapacchi, E., Squadrilli, A., Buti, S., Missale, G., and Ardizzoni, A.
Published: 2017
Full Text: View/download PDF

120. 2175 - Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis

Author: De Lisi, D., Maruzzo, M., Galli, L., Biasco, E., Farnesi, A., Procopio, G., Ratta, R., Buti, S., Sternberg, C.N., Cerbone, L., Di Lorenzo, G., Pantano, F., Sterpi, M., De Giorgi, U., Berardi, R., Torinai, M., Camerini, A., Massari, F., Tonini, G., and Santini, D.
Published: 2017
Full Text: View/download PDF

121. Renal Metastases to Pancreas: Do not Operate All and Always?

Author: Burattini, L., primary, Santoni, M., additional, Porta, C., additional, Sternberg, C.N., additional, Procopio, G., additional, Basso, U., additional, De Giorgi, U., additional, Rizzo, M., additional, Ortega, C., additional, Massari, F., additional, Masini, C., additional, Milella, M., additional, Di Lorenzo, G., additional, Cerbone, L., additional, Conti, A., additional, Buti, S., additional, Partelli, S., additional, Falconi, M., additional, Santini, D., additional, and Cascinu, S., additional
Published: 2014
Full Text: View/download PDF

122. 39P - LOH as “the missing instability” potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer

Author: Bersanelli, M., Gnetti, L., Azzoni, C., Bottarelli, L., Gasparro, D., Leonardi, F., Silini, E.M., and Buti, S.
Published: 2016
Full Text: View/download PDF

123. 832P - First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

Author: Bersanelli, M., Maines, F., Facchini, G., Gelsomino, F., Zustovich, F., Santoni, M., Verri, E., De Giorgi, U., Masini, C., Morelli, F., Vitale, M.G., Sava, T., Prati, G., Librici, C., Fraccon, A.P., Fornarini, G., Maruzzo, M., Leonardi, F., Caffo, O., and Buti, S.
Published: 2016
Full Text: View/download PDF

124. C10 - First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

Author: Bersanelli, M., Maines, F., Facchini, G., Gelsomino, F., Zustovich, F., Santoni, M., Verri, E., De Giorgi, U., Masini, C., Morelli, F., Vitale, M.G., Sava, T., Prati, G., Librici, C., Fraccon, A.P., Fornarini, G., Maruzzo, M., Leonardi, F., Caffo, O., and Buti, S.
Published: 2016
Full Text: View/download PDF

125. P118 Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)

Author: Caffo, O., primary, Lo Re, G., additional, Sava, T., additional, Buti, S., additional, Sacco, C., additional, Basso, U., additional, Zustovich, F., additional, Martini, T., additional, Perin, A., additional, Veccia, A., additional, Russo, L.M., additional, Facchini, G., additional, Barile, C., additional, Gernone, A., additional, De Vivo, R., additional, Pappagallo, G., additional, and Galligioni, E., additional
Published: 2012
Full Text: View/download PDF

126. Erythrocyte Mean Corpuscular Volume Change During Pemetrexed Treatment in Advanced Non Small Cell Lung Cancer Patients

Author: Buti, S., primary, Bordi, P., additional, Tiseo, M., additional, Panni, S., additional, Novello, S., additional, Bria, E., additional, Rapetti, S.G., additional, Pilotto, S., additional, Camisa, R., additional, and Ardizzoni, A., additional
Published: 2012
Full Text: View/download PDF

127. F14 - Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

Author: Santini, D., Santoni, M., Conti, A., Procopio, G., Verzoni, E., Galli, L., Di Lorenzo, G., De Giorgi, U., De Lisi, D., Nicodemo, M., Maruzzo, M., Massari, F., Buti, S., Biasco, E., Ricotta, R., Porta, C., Vincenzi, B., Marchetti, P., Cascinu, S., and Tonini, G.
Published: 2015
Full Text: View/download PDF

128. Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study.

Author: Dalla Chiesa, M., primary, Poli, R., additional, Tomasello, G., additional, Lazzarelli, S., additional, Buti, S., additional, Brighenti, M., additional, Negri, F., additional, Curti, A., additional, Auzzani, A., additional, and Passalacqua, R., additional
Published: 2010
Full Text: View/download PDF

129. Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG).

Author: Passalacqua, R., primary, Buti, S., additional, Brighenti, M., additional, Rivoltini, L., additional, Castelli, C., additional, Camisaschi, C., additional, Simonelli, C., additional, Lo Re, G., additional, Mattioli, R., additional, and Lazzarelli, S., additional
Published: 2010
Full Text: View/download PDF

130. High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC)

Author: Dalla Chiesa, M., primary, Tomasello, G., additional, Buti, S., additional, Negri, F., additional, Brighenti, M., additional, Lazzarelli, S., additional, Auzzani, A., additional, Curti, A., additional, Martinotti, M., additional, and Passalacqua, R., additional
Published: 2008
Full Text: View/download PDF

131. Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)

Author: Passalacqua, R., primary, Buti, S., additional, Rivoltini, L., additional, Castelli, C., additional, Camisaschi, C., additional, Simonelli, C., additional, Lo Re, G., additional, Mattioli, R., additional, Mazza, G., additional, Brighenti, M., additional, and Lazzarelli, S., additional
Published: 2008
Full Text: View/download PDF

132. Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)

Author: Passalacqua, R., primary, Buzio, C., additional, Buti, S., additional, Labianca, R., additional, Porta, C., additional, Boni, C., additional, Rondini, E., additional, Camisa, R., additional, Sabbatini, R., additional, Artioli, F., additional, and Caminiti, C., additional
Published: 2007
Full Text: View/download PDF

133. Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study

Author: Dalla Chiesa, M., primary, Tomasello, G., additional, Buti, S., additional, Negri, F., additional, Buononato, M., additional, Longarini, R., additional, Porzio, R., additional, Lazzarelli, S., additional, Brighenti, M., additional, and Passalacqua, R., additional
Published: 2007
Full Text: View/download PDF

134. Gefitinib (G) plus interleukin-2 (IL-2) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Author: Tomasello, G., primary, Buti, S., additional, Bosio, G., additional, Stifani, I., additional, Maestrelli, M., additional, Brighenti, M., additional, Porzio, R., additional, Lazzarelli, S., additional, Negri, F., additional, Longarini, R., additional, and Passalacqua, R., additional
Published: 2007
Full Text: View/download PDF

135. Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial

Author: Buti, S., primary, Lazzarelli, S., additional, Simonelli, C., additional, Venturini, S., additional, Spazzapan, S., additional, Lo Re, G., additional, Mattioli, R., additional, Dalla Chiesa, M., additional, Brighenti, M., additional, and Passalacqua, R., additional
Published: 2007
Full Text: View/download PDF

136. Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study

Author: Dalla Chiesa, M., primary, Tomasello, G., additional, Buti, S., additional, Negri, F., additional, Buononato, M., additional, Lazzarelli, S., additional, Brighenti, M., additional, Donati, G., additional, Cattaneo, M., additional, and Passalacqua, R., additional
Published: 2006
Full Text: View/download PDF

137. Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)

Author: Passalacqua, R., primary, Buzio, C., additional, Dalla Chiesa, M., additional, Camisa, R., additional, Porta, C., additional, Labianca, R., additional, Frassoldati, A., additional, Buti, S., additional, Pezzuolo, D., additional, Tomasello, G., additional, and Caminiti, C., additional
Published: 2005
Full Text: View/download PDF

138. 827P - Renal Metastases to Pancreas: Do not Operate All and Always?

Author: Burattini, L., Santoni, M., Porta, C., Sternberg, C.N., Procopio, G., Basso, U., De Giorgi, U., Rizzo, M., Ortega, C., Massari, F., Masini, C., Milella, M., Di Lorenzo, G., Cerbone, L., Conti, A., Buti, S., Partelli, S., Falconi, M., Santini, D., and Cascinu, S.
Published: 2014
Full Text: View/download PDF

139. Evaluation of the effect of organic modifier on pK values of diuretics in mobile phases used in LC

Author: Barbosa, J, primary, Barrón, D, additional, Bergés, R, additional, Buti, S, additional, and Sanz-Nebot, V, additional
Published: 1998
Full Text: View/download PDF

140. Nivolumab+ipilimumab (NIVO+IPI) adjuvant versus placebo dans le carcinome rénal localisé à haut risque de récidive après néphrectomie : résultats de l’étude de phase 3 randomisée Checkmate 914 (CM914)

Author: Barthélémy, P., Motzer, R., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Goh, J., Ye, D., Lingua, A., Lattouf, J., Escudier, B., George, S., Shuch, B., Simsek, B., Spiridigliozzi, J., Chudnovsky, A., and Bex, A.
Abstract: NIVO+IPI a démontré une amélioration de la survie globale versus sunitinib dans le CCR métastatique (NEJM2018 ;378 :1277–90). CM914, est une étude de phase 3, randomisée, en double aveugle, multicentrique, évaluant NIVO+IPI versus placebo (partie-A) ou NIVO monothérapie versus NIVO+IPI versus placebo (partie-B), chez des patients atteints de CCR localisé à haut risque de récidive après néphrectomie. Nous rapportons ici la première analyse de la partie-A.
Published: 2022
Full Text: View/download PDF

141. Standard pH values for standardization of potentiometric sensors in 10% (w/w) acetonitrile-water mixtures

Author: BARBOSA, J, primary, BUTI, S, additional, and SANZNEBOT, V, additional
Published: 1994
Full Text: View/download PDF

142. 1355 - Erythrocyte Mean Corpuscular Volume Change During Pemetrexed Treatment in Advanced Non Small Cell Lung Cancer Patients

Author: Buti, S., Bordi, P., Tiseo, M., Panni, S., Novello, S., Bria, E., Rapetti, S.G., Pilotto, S., Camisa, R., and Ardizzoni, A.
Published: 2012
Full Text: View/download PDF

143. Influence of a Spirulina platensisBiomass on the Microflora of Fermented ABT Milks During Storage (R1)

Author: Varga, L., Szigeti, J., Kovács, R., Földes, T., and Buti, S.
Abstract: The objective of this research was to investigate the effect of a cyanobacterial (Spirulina platensis) biomass on the microflora of a probiotic fermented dairy product during storage at two temperatures. Spirulina-enriched and control (plain) fermented acidophilusbifidus-thermophilus (ABT) milks were produced using a fast fermentation starter culture (ABT-4) as the source of Lactobacillus acidophilus(A), bifidobacteria (B), and Streptococcus thermophilus(T). Incubation took 6 h at 40°C. As for the cyanobacterial product, the S. platensisbiomass was added to the process milk during stirring at pH 4.5 to 4.6. Thereafter, the ABTtype fermented milks were cooled to 25°C in ice water, filled into sterile, tightly capped centrifuge tubes, further cooled at 4°C for 24 h, and then stored either at 15°C for 18 d or at 4°C for 42 d. Microbiological analyses and acidity measurements were performed at regular intervals. Our results showed that the counts of the starter organisms were satisfactory during the entire storage period at both temperatures applied in this research. The S. platensisbiomass had a beneficial effect on the survival of ABT starter bacteria regardless of storage temperature. Postacidification was observed at 15°C, whereas pH remained stable during refrigerated storage at 4°C. The abundance of bioactive substances in S. platensisis of great importance from a nutritional point of view because thus the cyanobacterial biomass provides a new opportunity for the manufacture of functional dairy foods.
Published: 2002
Full Text: View/download PDF

144. On the role of solvent in acid-base equilibria of diuretics in acetonitrile-water mixed solvents

Author: Barbosa, J., Barron, D., Beltran, J. L., and Buti, S.
Published: 1998
Full Text: View/download PDF

145. Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts

Author: Hirsh V, Pignata S, Bersanelli M, Gnetti L, Azzoni C, Bottarelli L, Gasparro D, Leonardi F, Em, Silini, Buti S, Wennerberg E, Mediero A, Cronstein B, Formenti S, Demaria S, Vanpouille-Box C, Pilones K, Rudqvist N, and Diamond J

146. BEVACIZUMAB (B) PLUS IMMUNOTHERAPY (IT) PLUS CHEMOTHERAPY (C) (BIC) IN METASTATIC RENAL CELL CANCER (MRCC): RESULTS AND EVALUATION OF CIRCULATING T-REGULATORY CELLS (TREG) AND OTHER CYTOKINES. A GOIRC STUDY

Author: Passalacqua, R., Buti, S., Simonelli, C., Rivoltini, L., Castelli, C., Camisaschi, C., Lo Re, G., Arben Lleshi, Donnini, M., and Lazzarelli, S.

147. Retroperitoneal cystoadenocarcinoma: A case report with a literature review

Author: Zanoni, D., Sikokis, A., Melissa Bersanelli, Gnetti, L., and Buti, S.

148. Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial

Author: Buti, S., Lazzarelli, S., Simonelli, C., Venturini, S., Spazzapan, S., Giovanni Lo Re, Mattioli, R., Chiesa, M. Dalla, Brighenti, M., and Passalacqua, R.

149. FINAL RESULTS OF A DOSE-FINDING PHASE II TRIAL WITH A TRIPLE COMBINATION THERAPY IN METASTATIC RENAL CELL CANCER (MRCC): BEVACIZUMAB (B) PLUS IMMUNOTHERAPY (IT) PLUS CHEMOTHERAPY (C) (BIC). ANTITUMOR EFFECTS AND VARIATIONS OF CIRCULATING T-REGULATORY CELLS (TREG) AND OTHER T LYMPHOCYTES SUBSETS

Author: Passalacqua, R., Buti, S., Brighenti, M., Licia Rivoltini, Castelli, C., Camisaschi, C., Simonelli, C., Lo Re, G., Mattioli, R., Mazza, G., Dalla Chiesa, M., Tomasello, G., Negri, F., and Lazzarelli, S.

150. PEMETREXED VERSUS PEMETREXED PLUS CARBOPLATIN IN PRETREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

Author: Tiseo, Marcello, Ardizzoni, Andrea, Luca Boni, Vincent, A., Buti, S., Camerini, Andrea, Labianca, R., Genestreti, Giovenzio, Zanelli, Francesca, Ciuffreda, L., Di Costanzo, F., Marinis, F., Crino, Lucio, Santo, A., Pazzola, A., Barbieri, F., Zilembo, N., Colantonio, I., Tibaldi, C., and Smit, Egbert F.

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

580 results on '"Buti S"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources